Janux Therapeutics (JANX)

• Market cap: $920M
• 1 day: -0.39%
• 5 days: -8.6%
• 1 month: -46.35%
• 3 months: -36.38%
• 6 months: -40.14%
• Year to date: -71.26%
• 1 year: -75.12%
• 5 years: -39.17%
• 10 years: -39.17%
• Sector: Healthcare
• Industry: Biotechnology

About: Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Employees: 109